AVITA Medical Announces Exclusive Distribution Agreement with Stedical Scientific

January 10, 2024

https://www.globenewswire.com/news-release/2024/01/10/2807475/0/en/AVITA-Medical-Announces-Exclusive-Distribution-Agreement-with-Stedical-Scientific.html

VALENCIA, Calif., Jan. 10, 2024 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ:RCEL, ASX:AVH) (the “Company”), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cellular therapies for skin restoration, today announced it has entered into an exclusive multi-year distribution agreement with Stedical Scientific, Inc. to commercialize PermeaDerm® Biosynthetic Wound Matrix in the United States. PermeaDerm is cleared by the Food and Drug Administration as a transparent matrix for use in the treatment of a variety of wound types until healing is achieved.

Read more at globenewswire.com

Related news for (RCEL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.